Inhibikase Therapeutics (IKT)

• Market cap: $203M
• 1 day: 5.03%
• 5 days: 7.74%
• 1 month: 4.37%
• 3 months: 8.44%
• 6 months: -1.76%
• Year to date: -49.24%
• 1 year: -54.25%
• 5 years: -97.19%
• 10 years: -97.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Employees: 16